Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolving therapies for Fuchs' endothelial dystrophy.

Yu Qiang Soh1,2, Gary Sl Peh1,3, Jodhbir S Mehta1,2,3,4

  • 1Tissue Engineering & Stem Cell Group, Singapore Eye Research Institute, 168751, Singapore.

Regenerative Medicine
|January 24, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cataract surgery with corneal endothelial pathology.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society·2026
Same author

Metabolic and redox adaptations of the corneal endothelium: From metabolic plasticity to therapeutic opportunities.

Redox biology·2026
Same author

Longitudinal Study of <i>TCF4</i> CTG Trinucleotide Repeat Length and Disease Severity in Fuchs' Endothelial Corneal Dystrophy.

Medical sciences (Basel, Switzerland)·2026
Same author

Management of positive and negative dysphotopsia postcataract surgery - A literature review.

Taiwan journal of ophthalmology·2026
Same author

Presbyopia intraocular lens in aberrated corneas.

Taiwan journal of ophthalmology·2026
Same author

Mitochondria in corneal physiology and pathology: A mechanistic perspective.

Progress in retinal and eye research·2025

Fuchs

Area of Science:

  • Ophthalmology
  • Corneal Diseases
  • Regenerative Medicine

Background:

  • Fuchs' endothelial dystrophy (FED) causes corneal dysfunction and is a leading cause for corneal transplants.
  • Current standard treatment for severe FED is keratoplasty (corneal transplant).

Purpose of the Study:

  • To review novel therapeutic strategies for Fuchs' endothelial dystrophy.
  • To evaluate regenerative and gene therapy as alternatives to keratoplasty.

Main Methods:

  • Review of recent advancements in FED treatment.
  • Analysis of regenerative approaches like descemetorhexis and tissue engineering.
  • Assessment of potential gene therapy based on CTG18.1 repeat expansion.

Main Results:

Keywords:
corneagene therapykeratoplastyophthalmologyregenerationtranslational studiestransplantation

Related Experiment Videos

  • Regenerative therapies show promise as alternatives to keratoplasty.
  • Gene therapy targeting CTG18.1 expansion is a future possibility.
  • Novel treatments aim to address corneal endothelial dysfunction.

Conclusions:

  • Emerging therapies offer potential alternatives to corneal transplantation for FED.
  • Understanding the genetic basis of FED may lead to groundbreaking treatments.
  • Further research into regenerative and gene therapies is warranted.